LOADING
Comparing Merck & Company (MRK) and Salesforce Inc (CRM) across the Health Care and Technology sectors. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | MRK | CRM |
|---|---|---|
| Price | $111.58 | $174.59 |
| Change Today | -1.62% | +4.18% |
| Market Cap | $280.2B | $135.7B |
| P/E Ratio | 32.0 | 21.3 |
| Forward P/E | 22.0 | 13.8 |
| PEG Ratio | 5.18 | 0.99 |
| EPS | $3.55 | $7.79 |
| Revenue Growth (YoY) | 4.9% | 12.1% |
| Profit Margin | 13.6% | 18.0% |
| Return on Equity | 18.9% | 12.4% |
| Dividend Yield | 2.92% | 0.97% |
| Beta | 0.20 | 1.14 |
| 52-Week High | $124.22 | $290.01 |
| 52-Week Low | $71.76 | $163.52 |
| Volume | 177K | 154K |
Merck & Company is the larger company by market capitalization. Salesforce Inc trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Merck & Company offers a higher dividend yield for income investors. Salesforce Inc has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.